CINECA IRIS Institutional Research Information System

MASI, GIANLUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.539
AS - Asia 13.450
EU - Europa 9.075
SA - Sud America 1.955
AF - Africa 515
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 10
Totale 50.570
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.770
SG - Singapore 4.416
CN - Cina 3.569
IT - Italia 3.180
HK - Hong Kong 2.144
BR - Brasile 1.605
SE - Svezia 1.218
VN - Vietnam 1.138
DE - Germania 827
BG - Bulgaria 753
CA - Canada 575
GB - Regno Unito 546
FR - Francia 500
TR - Turchia 467
UA - Ucraina 435
FI - Finlandia 420
RU - Federazione Russa 412
JP - Giappone 368
KR - Corea 304
IN - India 276
CH - Svizzera 219
CI - Costa d'Avorio 178
BD - Bangladesh 156
AR - Argentina 131
AT - Austria 120
NL - Olanda 111
IQ - Iraq 104
MX - Messico 88
ID - Indonesia 80
PL - Polonia 77
PK - Pakistan 67
ZA - Sudafrica 62
VE - Venezuela 55
ES - Italia 54
UZ - Uzbekistan 51
SN - Senegal 50
EC - Ecuador 49
SA - Arabia Saudita 46
MA - Marocco 45
NG - Nigeria 39
CO - Colombia 34
PH - Filippine 32
BE - Belgio 30
MY - Malesia 28
KE - Kenya 27
CZ - Repubblica Ceca 26
EG - Egitto 26
PY - Paraguay 24
AE - Emirati Arabi Uniti 21
JO - Giordania 21
TN - Tunisia 20
LT - Lituania 19
PT - Portogallo 18
CL - Cile 17
IL - Israele 17
JM - Giamaica 17
NP - Nepal 17
BJ - Benin 16
CR - Costa Rica 15
IE - Irlanda 15
UY - Uruguay 15
AU - Australia 14
DZ - Algeria 14
GR - Grecia 14
IR - Iran 14
PE - Perù 13
OM - Oman 12
PA - Panama 12
BO - Bolivia 11
NZ - Nuova Zelanda 11
TH - Thailandia 11
AZ - Azerbaigian 10
RO - Romania 10
TW - Taiwan 10
HN - Honduras 9
LB - Libano 9
TT - Trinidad e Tobago 9
DO - Repubblica Dominicana 8
ET - Etiopia 8
KH - Cambogia 8
NI - Nicaragua 8
AL - Albania 7
EU - Europa 7
HU - Ungheria 7
KZ - Kazakistan 7
SY - Repubblica araba siriana 7
BB - Barbados 6
DK - Danimarca 6
GT - Guatemala 6
HR - Croazia 6
LV - Lettonia 6
PS - Palestinian Territory 6
KG - Kirghizistan 5
LU - Lussemburgo 5
NO - Norvegia 5
SK - Slovacchia (Repubblica Slovacca) 5
AM - Armenia 4
AO - Angola 4
BY - Bielorussia 4
EE - Estonia 4
Totale 50.482
Salva come PNG Salva come JPEG
Città #
Woodbridge 3.005
Ashburn 2.578
Singapore 2.467
Hong Kong 2.105
Ann Arbor 1.916
Houston 1.496
San Jose 1.475
Fairfield 1.434
Santa Clara 1.309
Chandler 1.207
Milan 1.080
Dallas 1.074
Shanghai 759
Sofia 752
Seattle 671
New York 605
Jacksonville 600
Beijing 588
Cambridge 573
Wilmington 568
Boardman 511
Ottawa 460
Hefei 449
Los Angeles 412
Tokyo 333
Princeton 311
Lawrence 301
Ho Chi Minh City 294
Lauterbourg 286
Izmir 285
Seoul 282
Medford 266
Nanjing 262
Serra 243
Council Bluffs 212
Bern 199
Hanoi 190
Dearborn 181
Abidjan 178
Buffalo 162
Florence 158
London 153
Pisa 151
Munich 130
Rome 129
Des Moines 127
Istanbul 124
Redondo Beach 122
São Paulo 116
Helsinki 113
Dong Ket 110
Nanchang 106
Düsseldorf 104
Jüchen 102
San Diego 97
Frankfurt am Main 88
Vienna 88
Redwood City 84
Cascina 73
Ogden 67
Nuremberg 65
Warsaw 65
Kunming 63
Orem 62
Turku 61
Columbus 58
Shenyang 58
Chicago 53
Boulder 50
Dakar 50
Bremen 49
Changsha 47
Hebei 46
Lancaster 46
Da Nang 44
Rio de Janeiro 44
Baghdad 41
Tashkent 41
Montreal 40
Phoenix 40
Haiphong 38
Tianjin 38
Fuzhou 37
Guangzhou 36
Lagos 36
Norwalk 35
Belo Horizonte 33
The Dalles 33
Brasília 32
Mumbai 32
Denver 31
Dhaka 31
Brooklyn 30
Genoa 30
Hyderabad 30
Pune 30
Manchester 29
San Francisco 29
Toronto 29
Chennai 28
Totale 35.991
Salva come PNG Salva come JPEG
Nome #
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 279
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 252
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 244
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 244
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach 221
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 219
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 218
OUTCOME OF SECOND-LINE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY WITH THE GONO FOLFOXIRI REGIMEN. 217
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer 206
FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis 199
Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study 198
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group 198
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 198
Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC) 195
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer 194
Optimal approach to potentially resectable liver metastases from colorectal cancer 192
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 192
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 192
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 192
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 191
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis 190
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) 189
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 189
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 189
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer 188
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine 188
Techniques of parenchyma-sparing hepatectomy for the treatment of tumors involving the hepatocaval confluence: A reliable way to assure an adequate future liver remnant volume 188
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 187
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 187
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 186
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 185
TAS-102 for the treatment of metastatic colorectal cancer 184
Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy? 183
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 182
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 182
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts) 181
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 181
Management of peritoneal carcinomatosis with cytoreductive surgery combined with intraperitoneal chemohyperthermia at a novel italian center 181
Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey 180
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 179
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 179
Long-term outcome of unresectable metastatic colorectal cancer: does “adjuvant” chemotherapy play a role after resection? 178
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 178
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 178
Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy 177
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 177
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer 176
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 176
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 176
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 175
Variations in the Interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer 174
A PHASE ii TRIAL OF FIXED-DOSE RATE GEMCITABINE PLUS CAPECITABINE IN METASTATIC/ADVANCED BILIARY TRACT CANCER PATIENTS. 174
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 173
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle 173
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 172
Palliative treatment of unresectable metastatic colorectal cancer 172
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 172
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus beva s first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. 172
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials 171
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 171
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (MCRC) patients 170
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 170
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 169
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 169
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 169
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 168
Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 167
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 167
Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI 167
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment 167
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 167
Second-line treatments in patients with metastatic colorectal cancer progressed after first-line FOLFOXIRI 166
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial 166
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 166
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 165
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 165
VEGF gene polymorphisms in the prediction of benefit from first-line folfiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 165
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 165
REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives 164
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by irinotecan (Ir) + 5-FU/LV (IrFL) followed by docetaxel (T) + 5-FU/LV (TFL) in patients (pts) with metastatic (M) gastric carcinoma (GC): Preliminary results of a phase II trial by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 164
Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 164
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 164
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 164
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 164
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer 164
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice 163
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 163
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 163
Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC) 162
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 162
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 162
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 161
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer 160
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy 160
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 159
Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 159
Epidermal growth factor receptor (EGFR) gene promoter methylation in primari colorectal tumours and corresponding metastatic sites: a new perspective for an “old”therapeutic target 159
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. 159
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 159
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 159
Totale 18.000
Salva come PNG Salva come JPEG
Categoria #
all - tutte 148.322
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 148.322
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.900 34 186 93 151 550 470 41 112 117 119 211 816
2022/20233.584 428 365 218 293 456 507 37 271 685 21 264 39
2023/20244.190 521 535 530 324 582 614 285 150 78 85 141 345
2024/202511.151 113 428 165 503 886 1.316 757 574 1.138 1.426 1.351 2.494
2025/202613.635 828 1.616 1.386 1.162 1.313 1.317 2.019 754 940 1.306 649 345
2026/2027111 111 0 0 0 0 0 0 0 0 0 0 0
Totale 51.290